Sébastien Roux

TL;DR: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.

TL;DR: Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension, suggesting that endothelin has an important role in pulmonary hypertension.

TL;DR: The primary objective in the Bosentan Use in Interstitial Lung Disease-3 trial was not met and bosentan was well tolerated.

TL;DR: Clazosentan significantly decreased moderate and severe vasospasms in a dose-dependent manner and showed a trend for reduction in vasospasm-related morbidity/mortality in patients with aneurysmal subarachnoid hemorrhage when centrally assessed.

TL;DR: Clazosentan at 5 mg/h had no significant effect on mortality and vasospasm-related morbidity or functional outcome and further investigation of patients undergoing endovascular coiling of ruptured aneurysms is needed to fully understand the potential usefulness of clazosetan in patients with aSAH.